MacroGenics, Inc. (MGNX)
Largest Insider Buys in Sector
MGNX Stock Price History Chart
MGNX Stock Performance
About MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug …
Insider Activity of MacroGenics, Inc.
Over the last 12 months, insiders at MacroGenics, Inc. have bought $0 and sold $5M worth of MacroGenics, Inc. stock.
On average, over the past 5 years, insiders at MacroGenics, Inc. have bought $12.92M and sold $2.38M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $669,585 was made by BIOTECH TARGET N V (10 percent owner) on 2023‑10‑02.
List of Insider Buy and Sell Transactions, MacroGenics, Inc.
| 2024-04-04 | Sale | Senior VP and General Counsel | 51,395 0.0725% | $15.55 | $799,148 | -76.31% | ||
| 2024-03-06 | Sale | Senior VP and General Counsel | 19,625 0.0317% | $21.50 | $421,938 | -79.66% | ||
| 2024-03-04 | Sale | SVP, CFO and Secretary | 30,000 0.0481% | $20.50 | $615,000 | -78.89% | ||
| 2024-03-04 | Sale | Chief Operating Officer | 41,159 0.0636% | $19.76 | $813,501 | -78.89% | ||
| 2024-03-04 | Sale | Sr VP, Technical Ops | 10,000 0.0156% | $20.00 | $200,000 | -78.89% | ||
| 2024-02-26 | Sale | Senior VP and General Counsel | 16,124 0.0266% | $17.22 | $277,655 | -73.59% | ||
| 2024-02-07 | Sale | Sr VP, Research & CSO | 3,334 0.0069% | $18.00 | $60,012 | -73.90% | ||
| 2024-02-05 | Sale | Senior VP and General Counsel | 76,251 0.1454% | $16.50 | $1.26M | -72.66% | ||
| 2024-02-01 | Sale | Sr VP, Research & CSO | 13,316 0.0231% | $15.00 | $199,740 | -69.68% | ||
| 2024-01-19 | Sale | Sr VP, Research & CSO | 13,316 0.0216% | $12.00 | $159,792 | -59.67% | ||
| 2023-12-20 | Sale | Sr VP, Research & CSO | 18,880 0.031% | $10.08 | $190,310 | -45.19% | ||
| 2023-10-02 | 10 percent owner | 150,000 0.2413% | $4.46 | $669,585 | +69.31% | |||
| 2023-09-07 | 10 percent owner | 200,000 0.324% | $5.26 | $1.05M | +42.05% | |||
| 2023-08-30 | director | 15,000 0.0244% | $4.91 | $73,650 | +52.96% | |||
| 2023-03-10 | Sale | Senior VP and General Counsel | 5,372 0.0099% | $6.03 | $32,393 | +19.55% | ||
| 2023-02-14 | 10 percent owner | 500,000 0.7819% | $5.07 | $2.53M | +15.84% | |||
| 2023-01-19 | director | 150,000 0.245% | $5.30 | $794,925 | +10.19% | |||
| 2022-12-27 | director | 200,000 0.3249% | $5.61 | $1.12M | +1.33% | |||
| 2022-12-23 | director | 200,000 0.3225% | $5.88 | $1.18M | -4.21% | |||
| 2022-11-22 | director | 300,000 0.471% | $5.96 | $1.79M | -7.93% |
Insider Historical Profitability
| Karrels James | SVP, CFO and Secretary | 171452 0.2732% | $3.24 | 1 | 3 | +137.87% |
| BIOTECH TARGET N V | 10 percent owner | 9929963 15.8213% | $3.24 | 19 | 0 | <0.0001% |
| Costa Paulo F | director | 59435 0.0947% | $3.24 | 1 | 0 | +41.83% |
| HURWITZ EDWARD | director | 33074 0.0527% | $3.24 | 1 | 1 | |
| Galbraith Kenneth | director | 0 0% | $3.24 | 1 | 1 | <0.0001% |
Institutional Investor Ownership
| Bellevue Group | $146.7M | 15.91 | 9.97M | +0.13% | +$184,721.28 | 2.25 | |
| Avoro Capital Advisors Llc | $90.53M | 9.82 | 6.15M | New | +$90.53M | 1.09 | |
| BlackRock | $83.85M | 9.09 | 5.7M | -7.23% | -$6.54M | <0.01 | |
| State Street | $64.62M | 7.01 | 4.39M | +101.91% | +$32.61M | <0.01 | |
| The Vanguard Group | $54.14M | 5.87 | 3.68M | -14.66% | -$9.3M | <0.01 |